Clinical Trial Update: Study of Niacin in Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating niacin for glioblastoma (IDH-wildtype) is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype

Drugs mentioned

• Niacin (nicotinic acid)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1, Phase 2 | Status: SUSPENDED